Abstract:Objective To explore the relationship between the response variability in patients with acute coronary syndrome (ACS) treated with clopidogrel and the recurrent cardiovascular events.Methods The ACS patients received loading dose of clopidogrel (300 mg/d) on the first day of hospitalization or before percutaneous coronary intervention,then received maintenance dose of clopidogrel (75 mg/d) from the second day,in addition,all patients received aspirin (100 mg/d) for one year.The patients' maximal aggregation rate (MAR) and inhibition of platelet aggregation(IPA) were measured before and 24 hours after administration of loading dose of clopidogrel.The patients were divided into non-response to clopidogrel,low-response to clopidogrel,and response to clopidogrel groups according to the IPA.The patients were followed-up at the end of 1,3,6,and 12 months after administration,respectively.The situation of recurrent cardiovascular (CV) events including cardiovascular death,acute and subacute stent thromboses,recurrent acute coronary artery syndrome,and ischemic stroke were recorded.The differences in accumulative incidence of recurrent CV events among the 3 groups were compared by Kaplan-Meier survival analysis.Results A total of 190 patients with ACS who were hospitalized in the Department of Cardiology,Zhongda Hospital,Southeast University from October 2009 to March 2013 were enrolled into the study,comprising 111 males and 79 females with an average age of (66.1 ± 7.8) years.There were 53,46,and 91 patients in the non-response to clopidogrel group,the low-response to clopidogrel group,and the response to clopidogrel group,respectively.The differences in the sex composition,combined risk factors,and drug combination among the 3 groups were not significant (all P ＞ 0.05).The average age in the nonresponse to clopidogrel group [(69.1 ±7.8) years] was older than that in the response to clopidogrel group [(64.3 ± 7.4) years] (P ＜ 0.05).The accumulative incidence of recurrent CV events on 1,3,6,and 12months in the non-response to clopidogrel group [11.3％ (6/53) 、20.8％ (11/53) 、22.6％ (12/53) and35.8％ (19/53) were significantly higher than those in the response to clopidogrel group [1.1％ (1/91)、1.1％ (1/91) 、2.2％ (2/91) and 9.9％ (9/91)] (all P ＜ 0.05).The results of Kaplan-Meier survival analysis showed that the accumulative incidence of recurrent CV events in the non-response to clopidogrel group were significantly higher than those in the low-response to clopidogrel group (P ＜ 0.05) and the response to clopidogrel group (P ＜ 0.01).Conclusions The response variability to clopidogrel of patient with ACS may be associated with recurrent CV events.The patient who received clopidogrel should be given the examination of MAR and IPA in order to decrease or avoid the recurrent CV events.

Progress of Research on Clopidogrel Resistance in the Patients with Acute Coronary Syndrome

Clinical analysis of clopidogrel resistance in patients with coronary heart disease after percutaneous coronary intervention

Recent Progress in Response Variability of Blood Platelets in Clopidogrel Resistance

Study on Genetic Factors of Clopidogrel Resistance

Research progress of antiplatelet drug "nonresponder"

Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives

Consideration and Implication of Clopidogrel Resistance in Era of Percutaneous Coronary Intervention: core recognition and benefit improvement

Effect of Clopidogrel on Aspirin Resistance in Acute Coronary Syndrome Patients

Antiplatelet agent resistance and prevention and treatment of stroke

Clopidogrel Resistance and Genetic Polymorphism

The research progress of CYP2C19 gene polymorphism and clopidogrel resistance

Related factors of clopidogrel resistance in patients receiving percutaneous coronary intervention for acute coronary syndrome

Incidence rates of clopidogrel resistance and influential factors in patients with acute coronary syndrome

Resistance of Acute Coronary Syndrome Patients to Antiplatelet Drugs and Its Correlation to COX-1 Gene

The Phenomenon of Clopidogrel High On-Treatment Platelet Reactivity in Ischemic Stroke Subjects: A Comprehensive Review

Clopidogrel resistance and its effect on clinical outcomes in acute coronary syndrome

The Role of Genetic Polymorphism and Other Factors on Clopidogrel Resistance (CR) in an Asian Population with Coronary Heart Disease (CHD)

Factors associated with clopidogrel resistance and clinical outcomes in ischemic cerebrovascular disease: A retrospective study

Relationship between the responsive variability to clopidogrel in patients with acute coronary syndrome and the recurrent cardiovascular events

Overcoming Clopidogrel Resistance: Three Promising Novel Antiplatelet Drugs Developed in China

Gene Polymorphisms of Insulin Secretion Signaling Pathway Associated with Clopidogrel Resistance in Han Chinese Population.